Design, synthesis, and biological evaluation of matrine derivatives possessing piperazine moiety as antitumor agents

被引:19
作者
Xu, Yiming [1 ]
Liang, Pengyun [1 ]
Ur Rashid, Haroon [1 ,2 ]
Wu, Lichuan [3 ]
Xie, Peng [1 ]
Wang, Haodong [1 ]
Zhang, Shuyan [1 ]
Wang, Lisheng [3 ]
Jiang, Jun [1 ]
机构
[1] Guangxi Univ, Sch Chem & Chem Engn, Nanning 530004, Peoples R China
[2] Sarhad Univ Sci & Informat Technol, Dept Chem, Peshawarkhyber 25120, Pakhtunkhwa, Pakistan
[3] Guangxi Univ, Med Coll, Nanning 530004, Peoples R China
基金
中国国家自然科学基金;
关键词
Piperazine; Matrine; Antiproliferative activity; Cisplatin;
D O I
10.1007/s00044-019-02398-2
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Using matrine (1) as the lead compound, a series of new piperazinyl matrine derivatives were designed, synthesized and evaluated for their antitumor activities in vitro and in vivo. Structure activity relationship (SAR) analysis indicated that introduction of substituted piperazine on matrine might significantly enhance the antiproliferative activity. Moreover, types of substituents of piperazine exhibited great different effects on the antiproliferative activity of target compounds against Bel-7402 and RKO cell lines. The in vivo antitumor assay results revealed that some of the target derivatives possessed better therapeutic efficacy than matrine and low toxicity. More importantly, among the newly synthesized compounds, M16 and M26 possessed strong antitumor activity against the two cell lines. Moreover, six of the synthesized compounds M1, M3, M7, M10, M11 and M17 proved to be of much better therapeutic efficacy than matrine via in vivo antitumor assay. The study provides a theoretical basis for further structural optimizations and discovery of the antitumor pathways of this kind of compounds.
引用
收藏
页码:1618 / 1627
页数:10
相关论文
共 15 条
[1]  
Aghvami Marjan, 2018, Asian Pac J Cancer Prev, V19, P555
[2]   Cancer therapy and vaccination [J].
Aly, Hamdy A. A. .
JOURNAL OF IMMUNOLOGICAL METHODS, 2012, 382 (1-2) :1-23
[3]   Matrine induces apoptosis in gastric carcinoma cells via alteration of Fas/FasL and activation of caspase-3 [J].
Dai, Zhi-jun ;
Gao, Jie ;
Ji, Zong-zheng ;
Wang, Xi-jing ;
Ren, Hong-tao ;
Liu, Xiao-xu ;
Wu, Wen-ying ;
Kang, Hua-feng ;
Guan, Hai-tao .
JOURNAL OF ETHNOPHARMACOLOGY, 2009, 123 (01) :91-96
[4]  
FAJAS L., 2011, Patent No. [WO/2011/030312, 2011030312]
[5]  
Jones P., 2011, Patent No. [WO/2011/036478, 2011036478]
[6]   Antioxidative activities of novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter [J].
Kimura, M ;
Masuda, T ;
Yamada, K ;
Kawakatsu, N ;
Kubota, N ;
Mitani, M ;
Kishii, K ;
Inazu, M ;
Kiuchi, Y ;
Oguchi, K ;
Namiki, T .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (16) :4287-4290
[7]   Determination of 1-aryl-4-propylpiperazine pKa values: The substituent on aryl modulates basicity [J].
Lacivita, Enza ;
Leopoldo, Marcello ;
De Giorgio, Paola ;
Berardi, Francesco ;
Perrone, Roberto .
BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (03) :1339-1344
[8]   Combination of Matrine and Sorafenib Decreases the Aggressive Phenotypes of Hepatocellular Carcinoma Cells [J].
Lin, Yan ;
Lin, Lianjie ;
Jin, Yu ;
Zhang, Ying ;
Wang, Dongxu ;
Tan, Yue ;
Zheng, Changqing .
CHEMOTHERAPY, 2014, 60 (02) :112-118
[9]   Piperazine derivatives for therapeutic use: a patent review (2010-present) [J].
Rathi, Anuj K. ;
Syed, Riyaz ;
Shin, Han-Seung ;
Patel, Rahul V. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2016, 26 (07) :777-797
[10]  
Schiemann K., 2010, [No title captured], Patent No. [2010/115491, 2010115491]